僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab （HY-P9913）. Urelumab can be used for the research of diffuse large B-cell lymphoma （DLBCL）, follicular lymphoma （FL）, and other types of non-Hodgkin lymphoma （NHL）